Second engine igniting off the first: an unplanned-for adjacent revenue stream has started paying, and management is now
The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes a second, distinct way of making money that emerged from existing operations, is already generating real paying business, and is being deliberately grown. Let's analyze the transcript. The company is Alkermes, with products like VIVITROL, ARISTADA, and pipeline. They also have manufacturing and royalty revenues from partnerships (e.g., RISPERDAL CONSTA, INVEGA, AMPYRA). They have R&D collaborations (e.g., with Biogen for BIIB098). They have an oncology candidate ALKS 4230. The question asks: does management describe a second, distinct way of making money that emerged from existing operations, assets, customers, or capabilities - an additional revenue avenue that grew out of what the company already does rather than a separate diversification - AND that this second avenue is already generating real paying business today while management is now deliberately putting effort or resources behind growing it? We need to look for a phenomenon where the company leverages something it already built for a new revenue stream. For example, maybe they are using their long-acting injectable technology for other products? Or they are monetizing their manufacturing capabilities? Or they are using their sales force for future products? But that's not yet paying. Let's read the transcript carefully. The company has three main revenue streams: proprietary products (VIVITROL, ARISTADA), manufacturing and royalty revenues (from partners like J&J for RISPERDAL CONSTA, INVEGA, and from Biogen for AMPYRA/FAMPYRA), and R&D revenues (from collaborations like Biogen for BIIB098). These are all part of their business model. They are not necessarily a "second avenue that grew out of the first" in the sense of a new distinct stream emerging from existing operations. They are multiple segments that have been there. The question is about a second avenue that emerged from existing operations, assets, customers, or capabilities. For example, maybe they are using their expertise in long-acting injectables to develop new products? But that's not a separate revenue stream yet. Look for any mention of a new business line that is already generating revenue and being grown. For instance, they mention expanding sales force for ARISTADA, but that's the same product. They mention preparing for 5461 and 3831, but those are not yet approved.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| CMLS | Cumulus Media Inc. | Q3 2022 | 2022-10-28 | D |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
LRN · Q1 2019 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows career readiness as a distinct second revenue avenue that emerged directly from the existing MPS business: students already enrolled in Managed Public Schools are being moved into career readiness programs (over 5,000 students), and the initiative is built on the same platform, curriculum, and student base. Management explicitly describes it as a “career readiness line of business” and “robust career readiness business” that is already generating paying enrollments today while they are deliberately investing resources—dedicated executives, reallocation of funds, and plans to drive a major portion of next year’s enrollment growth.
M · Q4 2022 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows that Macy’s Marketplace is explicitly described as a distinct new revenue avenue that emerged directly from their existing e-commerce operations and customer base (macys.com, cross-shoppers, and omnichannel platform). Jeff Gennette states it “captures incremental sales opportunity,” “drives a larger average order value,” “allows us to quickly move into new and adjacent categories without inventory risk,” and “attracts a new younger customer,” while management is actively scaling it by adding 2,000 brands in 2023 and launching Bloomingdale’s marketplace in the back half.
GDRX · Q2 2022 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows that Pharma Manufacturer Solutions is the second distinct revenue avenue that emerged from GoodRx’s existing operations. Trevor explicitly states: “Our distinct ability to reach both consumers and providers continues to be recognized by manufacturers as evidenced by the strong growth.” This capability originated from the core prescription-transactions platform and user base 3 years earlier (when other offerings were only ~5% of revenue). In Q2 2022 it generated $26.6 million (102% YoY growth) and is already producing real paying business.